Greenwich LifeSciences, Inc.
GLSI evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $226.0M
- Lead Asset:
- glsi-100 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for GLSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLSI
Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company advancing a Phase III immunotherapy trial (FLAMINGO-01) for breast cancer recurrence prevention, with no revenue to date and ongoing net losses.
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Greenwich LifeSciences, Inc..
Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company advancing a Phase III immunotherapy trial (FLAMINGO-01) for breast cancer recurrence prevention, with no revenue to date and ongoing net losses.
- Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences [sec_mda · as of 2026-06-01].
- The company has not generated any revenue and has incurred net losses; net losses were approximately $19.4 million for the year ended December 31, 2025 and $9.6 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-11].
- As of 2026-06-30, the latest reported net income was -$3.9M and shareholders' equity was $3.1M [sec].
- FLAMINGO-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive subjects with residual disease or high-risk pathologic complete response after trastuzumab-based therapy [sec_mda · as of 2026-06-01].
- The company is expanding FLAMINGO-01 into Europe with plans to open up to 150 sites globally [sec_mda · as of 2026-06-01].
What works
- GLSI-100 has received Fast Track designation from the FDA, which may expedite development and review [news · published 2026-01-27].
- The company is advancing a Phase III trial (FLAMINGO-01) with global expansion plans, including up to 150 sites in Europe, indicating a structured late-stage development program [sec_mda · as of 2026-06-01].
- Preliminary open-label data from the non-HLA-A*02 arm of FLAMINGO-01 showed a continued reduction in recurrence rate, suggesting potential efficacy [news · published 2026-03-17].
What to weigh
- The company has not generated any revenue and has incurred significant net losses, with a net loss of $3.9M in the latest reported period (as of 2026-06-30) [sec].
- Net losses have been increasing, from $17.4M in 2024 to $19.4M in 2025, and the company expects to continue incurring significant expenses and operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Shareholders' equity is relatively low at $3.1M as of 2026-06-30, which may limit financial flexibility [sec].
- The company is entirely dependent on the success of a single Phase III trial (FLAMINGO-01), with no other pipeline assets mentioned, creating a high concentration risk [sec_mda · as of 2026-06-01].
From the filings
Quoted directly from source documents.
The company is focused on a Phase III trial for GLSI-100 to prevent breast cancer recurrences.
“We are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences.”
SEC MD&A · June 1, 2026
The company has not generated any revenue and has incurred net losses.
“To date, we have not generated any revenue and we have incurred net losses.”
SEC MD&A · August 11, 2026
Net losses for the six months ended June 30, 2026 were $9.6 million.
“Our net losses were approximately $19.4 million and $17.4 million for the years ended December 31, 2025 and 2024, respectively and $9.6 million and $6.5 million for the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 11, 2026
The trial is expanding into Europe with plans for up to 150 sites.
“We are currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.”
SEC MD&A · June 1, 2026
Catalyst timeline
- 2022-12-16 · Phase 3 Start (FLAMINGO-01) — A randomized, multicenter, placebo-controlled Phase 3 study evaluating GLSI-100 in HER2/neu positive subjects began on this date.
Risks & what to watch (4)›
Key risks
- No revenue, ongoing losses — Company has no revenue and incurred net losses of $9.6M in H1 2026; expects continued losses [sec_mda · as of 2026-08-11].
- Single-product dependency — Entire pipeline is one Phase III trial (FLAMINGO-01); no other drug candidates mentioned [sec_mda · as of 2026-06-01].
- Low shareholders' equity — Shareholders' equity is $3.1M as of 2026-06-30, limiting financial cushion [sec].
- Clinical trial execution risk — Expanding to 150 sites globally may increase operational complexity and costs [sec_mda · as of 2026-06-01].
What to watch
- Progress and data readouts from the FLAMINGO-01 Phase III trial, including the blinded placebo-controlled arm [news · published 2026-03-17].
- Cash runway and financing updates, as the company expects continued operating losses [sec_mda · as of 2026-08-11].
- Expansion of clinical sites into Europe and enrollment milestones [sec_mda · as of 2026-06-01].
- Any regulatory interactions or updates on the Fast Track designation for GLSI-100 [news · published 2026-01-27].
Sources: Catalysts · News · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Greenwich LifeSciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Greenwich LifeSciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.85 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$6.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard portfolio management llc | 58,911 | $1.4M |
| bank of new york mellon corp | 46,523 | $1.1M |
| vanguard fiduciary trust co | 44,908 | $1.1M |
| goldman sachs group inc | 39,521 | $949K |
| ancora advisors llc | 37,500 | $901K |
| vanguard global advisers, llc | 10,335 | $248K |
| rhumbline advisers | 8,046 | $193K |
| jones financial companies lllp | 3,200 | $71K |
| farther finance advisors, llc | 1,319 | $30K |
| new york state common retirement fund | 1,200 | $29K |
Showing top 10 of 17 institutional holders of Greenwich LifeSciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 22.5%
- Days to cover
- 11.6
- Shares short
- 1,544,439
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GLSI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Greenwich LifeSciences, Inc.?
Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company advancing a Phase III immunotherapy trial (FLAMINGO-01) for breast cancer recurrence prevention, with no revenue to date and ongoing net losses.
What is Greenwich LifeSciences, Inc.'s lead drug candidate?
Greenwich LifeSciences, Inc.'s most advanced tracked candidate is glsi-100 (Phase 3) for Breast Cancer.
Who is the CEO of Greenwich LifeSciences, Inc.?
Mr. Snehal S. Patel is the chief executive officer of Greenwich LifeSciences, Inc. (GLSI).
Where is Greenwich LifeSciences, Inc. headquartered?
Greenwich LifeSciences, Inc. (GLSI) is headquartered in Stafford, TX, United States.
What therapeutic areas does Greenwich LifeSciences, Inc. focus on?
Greenwich LifeSciences, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.